Volition: Capital markets day 2022 highlights

Published on 19 May 2022

Volition is a multinational epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Last week, the Volition team hosted a capital markets day at the New York Stock Exchange. Many members of the team discussed the Volition story: what makes its platform unique, why the market opportunity is exciting, and what its near-term commercialisation strategy looks like. This video demonstrates some of the day’s key highlights.

Share this with friends and colleagues